Collection 5 (Sep 2024 - Aug 2025) Articles

Articles
Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice
Di Girolamo FG, Pellin L, Roni C, et al.
Journal:
Eur J Intern Med

First published: August 8, 2025 DOI: 10.1016/j.ejim.2025.106442
View
- Share
Articles
Cholesterol Crystals as Triggers of NLRP3 Inflammasome Activation in Atherosclerosis
Yalcinkaya M, Tall AR
Journal:
Curr Atheroscler Rep

First published: August 1, 2025 DOI: 10.1007/s11883-025-01323-w
View
- Share
Articles
Cardiovascular Risk Factor and Disease Mortality Among Asian Indian, Chinese, and Filipino Adults in the United States, 2018 to 2023
Aggarwal R, Wadhera RK, Chiu N, et al.
Journal:
Ann Intern Med

First published: July 29, 2025 DOI: 10.7326/ANNALS-25-00108
View
- Share
Articles
Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression
Bellomo TR, Bramel EE, Lee J, et al.
Journal:
Circulation

First published: July 28, 2025 DOI: 10.1161/CIRCULATIONAHA.124.073579
View
- Share
Articles
Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study
deGoma E, Walsh J, Georgakis MK
Journal:
Circ Genom Precis Med

First published: July 28, 2025 DOI: 10.1161/CIRCGEN.125.005103
View
- Share
Articles
Lipoprotein (a): A new target for pharmacological research and an option for treatment
Pirillo A, Catapano AL
Journal:
Eur J Intern Med

First published: July 24, 2025 DOI: 10.1016/j.ejim.2025.07.021
View
- Share
Articles
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial
Taub PR, Gutierrez A, Wewers D, et al.
Journal:
J Am Coll Cardiol

First published: July 22, 2025 DOI: 10.1016/j.jacc.2025.04.049
View
- Share
Articles
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics
McCarthy CP, Ballantyne CM, Blankstein R, et al.
Journal:
Am Heart J

First published: July 17, 2025 DOI: 10.1016/j.ahj.2025.07.012
View
- Share
Articles
Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: one-year follow-up of the Spanish subpopulation from the European SANTORINI study
Mostaza JM, Lahoz C, de Yébenes Castro MG, et al.
Journal:
Rev Clin Esp (Barc)

First published: July 15, 2025 DOI: 10.1016/j.rceng.2025.502344
View
- Share
Articles
Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease
Zheutlin AR, Handoo F, Luebbe S, et al.
Journal:
Eur Heart J

First published: July 4, 2025 DOI: 10.1093/eurheartj/ehaf472
View
- Share
Articles
Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials
Xie S, Galimberti F, Olmastroni E, et al.
Journal:
Atherosclerosis

First published: July 3, 2025 DOI: 10.1016/j.atherosclerosis.2025.120420
View
- Share
Articles
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson W, Barbagelata L, Lobo M, et al.
Journal:
J Clin Lipidol

First published: June 23, 2025 DOI: 10.1016/j.jacl.2024.12.016
View
- Share

1 2 3 4 … 10

Collection 5 (Sep 2024 - Aug 2025) Articles

Articles

Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice

Di Girolamo FG, Pellin L, Roni C, et al.

Articles

Cholesterol Crystals as Triggers of NLRP3 Inflammasome Activation in Atherosclerosis

Yalcinkaya M, Tall AR

Articles

Cardiovascular Risk Factor and Disease Mortality Among Asian Indian, Chinese, and Filipino Adults in the United States, 2018 to 2023

Aggarwal R, Wadhera RK, Chiu N, et al.

Articles

Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression

Bellomo TR, Bramel EE, Lee J, et al.

Articles

Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study

deGoma E, Walsh J, Georgakis MK

Articles

Lipoprotein (a): A new target for pharmacological research and an option for treatment

Pirillo A, Catapano AL

Articles

Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial

Taub PR, Gutierrez A, Wewers D, et al.

Articles

Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics

McCarthy CP, Ballantyne CM, Blankstein R, et al.

Articles

Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: one-year follow-up of the Spanish subpopulation from the European SANTORINI study

Mostaza JM, Lahoz C, de Yébenes Castro MG, et al.

Articles

Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease

Zheutlin AR, Handoo F, Luebbe S, et al.

Articles

Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials

Xie S, Galimberti F, Olmastroni E, et al.

Articles

Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis

Masson W, Barbagelata L, Lobo M, et al.

Articles

Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice

Di Girolamo FG, Pellin L, Roni C, et al.

Share

Articles

Cholesterol Crystals as Triggers of NLRP3 Inflammasome Activation in Atherosclerosis

Yalcinkaya M, Tall AR

Share

Articles

Cardiovascular Risk Factor and Disease Mortality Among Asian Indian, Chinese, and Filipino Adults in the United States, 2018 to 2023

Aggarwal R, Wadhera RK, Chiu N, et al.

Share

Articles

Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression

Bellomo TR, Bramel EE, Lee J, et al.

Share

Articles

Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study

deGoma E, Walsh J, Georgakis MK

Share

Articles

Lipoprotein (a): A new target for pharmacological research and an option for treatment

Pirillo A, Catapano AL

Share

Articles

Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial

Taub PR, Gutierrez A, Wewers D, et al.

Share

Articles

Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics

McCarthy CP, Ballantyne CM, Blankstein R, et al.

Share

Articles

Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: one-year follow-up of the Spanish subpopulation from the European SANTORINI study

Mostaza JM, Lahoz C, de Yébenes Castro MG, et al.

Share

Articles

Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease

Zheutlin AR, Handoo F, Luebbe S, et al.

Share

Articles

Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials

Xie S, Galimberti F, Olmastroni E, et al.

Share

Articles

Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis

Masson W, Barbagelata L, Lobo M, et al.

Share